- Home
- PHAR vs HLF Comparison
PHAR vs HLF Comparison
Compare PHAR & HLF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PHAR
- HLF
- Stock Information
- Founded
- PHAR 1988
- HLF 1980
- Country
- PHAR Netherlands
- HLF United States
- Employees
- PHAR N/A
- HLF N/A
- Industry
- PHAR Biotechnology: Pharmaceutical Preparations
- HLF Other Pharmaceuticals
- Sector
- PHAR Health Care
- HLF Health Care
- Exchange
- PHAR Nasdaq
- HLF Nasdaq
- Market Cap
- PHAR 951.7M
- HLF 877.4M
- IPO Year
- PHAR N/A
- HLF N/A
- Fundamental
- Price
- PHAR $13.14
- HLF $7.75
- Analyst Decision
- PHAR Strong Buy
- HLF Strong Buy
- Analyst Count
- PHAR 3
- HLF 4
- Target Price
- PHAR $30.00
- HLF $11.50
- AVG Volume (30 Days)
- PHAR 11.0K
- HLF 1.2M
- Earning Date
- PHAR 11-06-2025
- HLF 11-05-2025
- Dividend Yield
- PHAR N/A
- HLF N/A
- EPS Growth
- PHAR N/A
- HLF 285.96
- EPS
- PHAR N/A
- HLF 3.17
- Revenue
- PHAR $339,836,000.00
- HLF $4,928,500,000.00
- Revenue This Year
- PHAR $17.70
- HLF $1.02
- Revenue Next Year
- PHAR $12.25
- HLF $4.52
- P/E Ratio
- PHAR N/A
- HLF $2.53
- Revenue Growth
- PHAR 22.44
- HLF N/A
- 52 Week Low
- PHAR $7.31
- HLF $5.04
- 52 Week High
- PHAR $17.08
- HLF $10.83
- Technical
- Relative Strength Index (RSI)
- PHAR 42.37
- HLF 33.18
- Support Level
- PHAR $13.08
- HLF $8.50
- Resistance Level
- PHAR $14.10
- HLF $8.32
- Average True Range (ATR)
- PHAR 0.52
- HLF 0.27
- MACD
- PHAR -0.16
- HLF -0.06
- Stochastic Oscillator
- PHAR 0.00
- HLF 11.11
About PHAR Pharming Group N.V.
Pharming Group is a biopharmaceutical company focused in transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company is actively developing and commercializing a diverse portfolio of innovative treatments, including both biologics and small molecule therapies. Its commercial products are RUCONEST, approved for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema, or HAE; and Joenja (leniolisib), a small-molecule kinase inhibitor, developed for the treatment of activated phosphoinositide 3-kinase delta syndrome.
About HLF Herbalife Ltd.
Herbalife Ltd is an international nutrition company that provides health and wellness products to consumers in 95 markets, which consist of countries and territories, through their direct-selling business model. Companies' products are weight management, targeted nutrition, Energy, Sports and Fitness, Outer Nutrition and Literature, Promotional, and Other. Weight management generates the majority of revenue from products like Meal replacements, protein shakes, drink mixes, weight loss enhancers, and healthy snacks. Geographically, the main segments are North America, Latin America, EMEA, Asia Pacific regions, and China.